SPDL1 and cancer: Indeed, sPD-L1 and sLAG3 have been reported as prognosis factors of clinical evolution in several cancers (22); elevated sCTLA-4 levels correlated with clinical benefit in patients treated with Ipilimumab (23); sPD-L1 allowed to discriminate responder and non-responder non-small cell lung cancer patients receiving Nivolumab.